slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 39,751-39,780
Pages 10,126
Rows per page 30
Component
39,751-39,780 of 303,780
34
The chart shows a significant underperformance of 'Twins' compared to the S&P 500 and selected insurance peer groups.Houlihan Lokey | Investment Banking Pitch Book | 42 slides · Houlihan Lokey
Consulting deck Investment bank Beat · AppendixLoop · Voice Of Customer2 hits
38
The chart displays individual shareholder cost basis values as bars, with an orange dashed line for the average cost basis ($10.59) and a grey dashed line for the current share price ($3.15).Houlihan Lokey | Investment Banking Pitch Book | 42 slides · Houlihan Lokey
Consulting deck Investment bank Beat · Appendix2 hits
39
The table tracks quarterly changes in shareholdings for 11 major investors from Q4 2020 to Q3 2022, alongside quarterly VWAP and stock price ranges.Houlihan Lokey | Investment Banking Pitch Book | 42 slides · Houlihan Lokey
Consulting deck Investment bank Beat · Appendix2 hits
01
HSBC | Investor Conference Presentation Deck | 18 slidesHSBC | Investor Conference Presentation Deck | 18 slides · HSBC
Deck Investor relations 2 hits
01
Kymera | Results Presentation Deck | 63 slidesKymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Problem Identification2 hits
08
Includes a table of prevalence/incidence for specific indications and a biological pathway diagram.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Agitation2 hits
09
The slide uses a dual-panel layout: left shows tumor volume reduction over time with weekly dosing; right shows PK/PD relationship highlighting the 48-hour window of STAT3 knockdown.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Agitation2 hits
11
Clinical trial safety data presentation.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Agitation2 hits
17
Shows efficacy data (tumor volume) alongside PK/PD mechanism data (degradation over time).Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution2 hits
19
The slide highlights the absence of dose-limiting toxicities (DLTs) and serious adverse events (SAEs) in the initial dose cohorts.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution2 hits
21
The slide uses line charts for longitudinal PBMC data and a bar chart for tumor knockdown data, supported by summary tables.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution2 hits
24
The slide uses a biological pathway diagram to contrast the 'scaffolding' and 'kinase' roles of IRAK4, arguing that degradation blocks both, whereas inhibitors only block the kinase role.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution2 hits
26
Includes a mechanism of action diagram, a market data table, and a callout box for competitive limitations.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution2 hits
27
The slide outlines a multi-part clinical trial (Parts A, B, and C) with specific dosing, randomization, and outcome metrics.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution2 hits
34
Data represents Part C: 75 mg QD (fed). Error bars represent standard error (SE).Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution2 hits
49
Includes clinical photography, efficacy endpoint table, and biomarker data (cytokines and RNAseq).Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Action2 hits
50
The slide uses a comparison table to highlight the efficacy of KT-474 against external benchmarks.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Action2 hits
57
The slide uses a before-after framework to demonstrate clinical efficacy.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Action2 hits
58
Includes patient demographics, clinical efficacy table, before/after photos, and a line chart of cytokine/reactant levels.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Action2 hits
01
Nano Dimension | Results Presentation Deck | 16 slidesNano Dimension | Results Presentation Deck | 16 slides · Nano Dimension
Conference presentation Investor relations 2 hits
03
Nano Dimension | Results Presentation Deck | 16 slidesNano Dimension | Results Presentation Deck | 16 slides · Nano Dimension
Conference presentation Investor relations Beat · Attention2 hits
05
Nano Dimension | Results Presentation Deck | 16 slidesNano Dimension | Results Presentation Deck | 16 slides · Nano Dimension
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction2 hits
06
Nano Dimension | Results Presentation Deck | 16 slidesNano Dimension | Results Presentation Deck | 16 slides · Nano Dimension
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction2 hits
07
Nano Dimension | Results Presentation Deck | 16 slidesNano Dimension | Results Presentation Deck | 16 slides · Nano Dimension
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction2 hits
08
The chart highlights Nano Dimension's significantly higher capital runway compared to Markforged, Desktop Metal, and Velo3D.Nano Dimension | Results Presentation Deck | 16 slides · Nano Dimension
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction2 hits
09
The chart groups the first three acquisitions under the Nano Dimension brand, while showing Nanoscribe and ExOne separately.Nano Dimension | Results Presentation Deck | 16 slides · Nano Dimension
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction2 hits
10
Nano Dimension | Results Presentation Deck | 16 slidesNano Dimension | Results Presentation Deck | 16 slides · Nano Dimension
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction2 hits
21
The slide uses a visual metaphor of a wedge to show the widening gap between revenue and expenses over time.Reservoir | Investor Presentation Deck | 35 slides · Reservoir
Pitch deck Investor relations Beat · Traction2 hits
01
ROTH Capital Partners | Investment Banking Pitch Book | 28 slidesROTH Capital Partners | Investment Banking Pitch Book | 28 slides · Roth Capital Partners
Deck Investment bank Beat · Situation & Context2 hits
06
Includes footnotes regarding source, treasury shares, and share class voting rights.ROTH Capital Partners | Investment Banking Pitch Book | 28 slides · Roth Capital Partners
Deck Investment bank Beat · Problem & ComplicationLoop · Logic Chain2 hits